RLMD vs. RZLT, OPTN, CLRB, PMVP, CTXR, COYA, ALLK, RNAC, IMUX, and CUE
Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Rezolute (RZLT), OptiNose (OPTN), Cellectar Biosciences (CLRB), PMV Pharmaceuticals (PMVP), Citius Pharmaceuticals (CTXR), Coya Therapeutics (COYA), Allakos (ALLK), Cartesian Therapeutics (RNAC), Immunic (IMUX), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical preparations" industry.
Relmada Therapeutics (NASDAQ:RLMD) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Rezolute is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rezolute received 39 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 75.34% of users gave Rezolute an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Rezolute's return on equity of -51.81% beat Relmada Therapeutics' return on equity.
45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 18.0% of Relmada Therapeutics shares are held by company insiders. Comparatively, 20.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Relmada Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 616.33%. Rezolute has a consensus target price of $8.80, suggesting a potential upside of 243.75%. Given Relmada Therapeutics' higher probable upside, equities research analysts plainly believe Relmada Therapeutics is more favorable than Rezolute.
In the previous week, Rezolute had 4 more articles in the media than Relmada Therapeutics. MarketBeat recorded 11 mentions for Rezolute and 7 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.08 beat Rezolute's score of 0.27 indicating that Relmada Therapeutics is being referred to more favorably in the media.
Relmada Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
Summary
Rezolute beats Relmada Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Relmada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relmada Therapeutics Competitors List
Related Companies and Tools
